Paper · 41820966

HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance.

Li Y and 4 others. J Transl Med, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance. Papers, record 41820966. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41820966

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance.; PubMed
Journal: J Transl Med; PubMed
Year: 2026; PubMed
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41820966/; PubMed
DOI: https://doi.org/10.1186/s12967-026-07934-4; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13097974/; PubMed
The journal: https://conductscience.org/library/journal-index/101190741; PubMed
Citations, by iCite: 0; iCite
Revised in PubMed: 2026-09-01; PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Li Y	Ying
2	Wang Z	Zhuo
3	Gu M	Meichen
4	Huang F	Fuxue
5	Chang P	Pengyu	https://orcid.org/0000-0001-9047-7942

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Signal Transduction	Major topic
Drug Resistance, Neoplasm	Major topic
Receptor, ErbB-3	Major topic
Carcinogenesis	Major topic
Humans
Animals
Neoplasms

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References167

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	25,310,982	mTORC1 controls PNS myelination along the mTORC1-RXRγ-SREBP-lipid biosynthesis axis in Schwann cells.	Cell Rep	2014	https://conductscience.org/library/papers/25310982	PubMed
2	21,782,525	Neural crest cell lineage restricts skeletal muscle progenitor cell differentiation through Neuregulin1-ErbB3 signaling.	Dev Cell	2011	https://conductscience.org/library/papers/21782525	PubMed
4	32,535,106	Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.	Biochem Pharmacol	2020	https://conductscience.org/library/papers/32535106	PubMed
5	31,825,192	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.	N Engl J Med	2020	https://conductscience.org/library/papers/31825192	PubMed
6	40,908,353	Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.	Nat Med	2025	https://conductscience.org/library/papers/40908353	PubMed
7	11,334,436	Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression.	Diabetes	2001	https://conductscience.org/library/papers/11334436	PubMed
8	18,381,441	FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.	Cancer Res	2008	https://conductscience.org/library/papers/18381441	PubMed
9	16,818,711	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.	Clin Cancer Res	2006	https://conductscience.org/library/papers/16818711	PubMed
10	37,397,533	PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain.	Genes Dis	2023	https://conductscience.org/library/papers/37397533	PubMed
11	26,418,897	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.	Oncotarget	2015	https://conductscience.org/library/papers/26418897	PubMed

1 to 10 of 167

See all 167 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMID	Title	Journal	Year	In Papers
42,828,105	Methyltransferase-like 7B promotes M2-like macrophage polarization in lung adenocarcinoma via upregulating human epidermal growth factor receptor 3 expression and secretion.	Oncol Lett	2026	https://conductscience.org/library/papers/42828105

Source PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
ERBB3	2,065	PubTator's text mining	https://conductscience.org/library/genes/2065

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41820966

GET https://conductscience.org/api/papers/v1/41820966/references?page=2

API reference For AI assistants